Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
A major focus of recent research has been the development of effective ways of sensitizing
the patient's immune system to recognize the cancer as foreign. Allogeneic stem cell
transplantation represents a novel way of potentially achieving this goal. There is recent
evidence that non-myeloablative allogeneic stem cell transplantation provides effective
therapy for patients with metastatic renal cell carcinoma. Based on the preliminary reports
from other investigators treating patient with breast and ovarian cancer, the investigators
of this study would propose treating an expanded cohort of patients with any metastatic solid
tumor.
The principal endpoints of the trial will include incidence of durable engraftment, quality
of hematopoietic and immune reconstitution, extent of donor chimerism, incidence and severity
of acute and chronic graft versus host disease (GVHD), and incidence of long-term disease
free survival (DFS). The investigators will evaluate the tumor response of patients with
stable or progressive disease post-transplant to donor lymphocyte infusions (DLI). The
investigators will also study the effects of DLI on T-cell immunity in the recipients.